Shumei Kato

机构：UC San Diego Health System, University of California San Diego, Moores Cancer Center · ORCID：0000-0003-1193-1815

发表论文 426 篇 · 总被引 12150 次 · h-index 49

代表论文

• KRAS G12C inhibitor combination therapies: current evidence and challenge (2024 · Frontiers in Oncology · 被引 82)
• Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders (2025 · Cytokine & Growth Factor Reviews · 被引 55)
• Toll-like receptor 3: a double-edged sword (2025 · Biomarker Research · 被引 36)
• Tumor necrosis factor superfamily signaling: life and death in cancer (2024 · Cancer and Metastasis Reviews · 被引 32)
• Evolution of Precision Oncology, Personalized Medicine, and Molecular Tumor Boards (2026 · Hematology/Oncology Clinics of North America · 被引 20)
• Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study. (2024 · Journal of Clinical Oncology · 被引 19)